All In Biotech

Drug Trial Radar · NCT00333944

Study to Know the Efficacy of Higher Doses of Pralidoxime in Patients of Organophpsphorus Poisoning.

Effectiveness of High Dose Pralidoxime in the Treatment of Organophosphorus Pesticide Poisoning - a Randomised Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jun 6, 2006 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

May 2000

Primary completion

Not stated

Study completion Jun 2003

Sponsor

Lead sponsor
Giriraj HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 6, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether high doses of pralidoxime(PAM) are effective as compare to lower doses of PAM in the management of moderately sever organophosphorus poisoning patients.

Conditions

  • Acute Organophosphorus Pesticide Poisoning

Interventions

  • Pralidoxime(drug)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median atropine dose required in first 24 hours
  2. proportion of patients who required intubation or developed intermediate syndrome
  3. number of days ventilated and required ICU care

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Giriraj Hospital and Intensive Care Unit.

    Baramati. Pune District., Maharashtra, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.